GSK’s Seroxat CR and Tykerb included in the NRDL list

The Ministry of Human Resources and Social Security (MOHRSS) today announced the results of the national health insurance negotiations, and two GSK products, Tykerb (Lapatinib) and Seroxat CR (Paroxetine), are included in the national reimbursement drug list (NRDL). 

Tykerb (Lapatinib) is a drug used in targeted therapy of breast cancer and is patent protected in China. Seroxat CR (Paroxetine) is a drug used in first line therapy for clinical depression in the China market. 

Thomas Willemsen, General Manager, GSK China Pharmaceuticals & Vaccines, said, "The Chinese government is committed to including innovative medicines in the reimbursement drug list under the national health insurance programme. We are very honoured that we are able to participate in the negotiations led by the MOHRSS. Following our participation in the national drug price negotiation pilot with Viread last year, we again demonstrated our commitment to making innovative products accessibile and affordable to Chinese patients. "

 

As part of the ‘in China, with China, for China’ strategy, GSK China has:

  • Announced strategic partnership with academia to co-develop health big-data system and upgrade the management of respiratory diseases in June 2017.
  • The National Preventive Vaccination Services and Management Training Programme, helmed by the Chinese Preventive Medicine Association under the guidance of the National Health and Family Planning Commission, with the support of the China Centre for Disease Control and Prevention and the aid of GSK, was officially kicked off in June 2017.
  • Joined hands with the Home of Red Ribbon to combat HIV/AIDS, unveiling plan to support people living with HIV in Nov 2016.
  • Announced the strategic partnership with China Preventive Medicine Association (CPMA) to address major public health challenges in China in Nov 2016.
  • Announced the approval of Cervarix in China to help protect women from cervical cancer in July 2016.
  • Announced a Memorandum of Understanding between the GSK Institute for Infectious Diseases and Public Health and Tsinghua University to tackle global public health challenges in June 2016.
  • Launched Tivicay, an innovative HIV drug, in June 2016.
  • Participated in the national price negotiation pilot and announced a price reduction of our first line chronic hepatitis B treatment, Viread, by up to 67% in May 2016.
  • Announced a Beijing-based Institute for Infectious Disease and Public Health to conduct local development programmes for pivotal HIV and TB R&D assets in March 2016.
  • Partnered with the National Health and Family Planning Commission on a multi-year programme to fund independent training programmes in Hepatitis and COPD for over 13,000 healthcare professionals from September 2015.
  • Formalised a partnership with Shanghai-based Desano Pharmaceuticals to locally manufacture the Active Pharmaceutical Ingredient for Tivicay (dolutegravir) in July 2015.
  • Transformed our commercial operating model to actively contribute to improving the quality of scientific exchanges with healthcare professionals for the benefit of patients since May 2015.

 

 

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com.

 

GSK commitment to China

We are a science-led global healthcare company. We research, develop and manufacture a wide range of medicines, vaccines and consumer healthcare products. People are at the heart of what we do. We strive to bring high quality, high performing products to everyone who needs them. Creating innovative products and improving access to them is critical to our mission, allowing us to help build stronger, healthier communities. In China, and around the world, we are on a mission to help people do more, feel better, live longer. We are in China, with China, for China, and our commitment remains unwavering.

 

GSK enquiries:

Susan Song            susan.s.song@gsk.com      (China)

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2016.